- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COTA and Foundation Medicine Collaboration Will Further Value-Based Cancer Care
COTA will expand Foundation Medicine's molecular information knowledge base with longitudinal clinical outcomes and cost of care data and analytics.
Foundation Medicine, Inc. (FMI) and COTA, Inc. today announced an agreement to capture and analyze comprehensive genomic, clinical outcome, and cost data from patients who have undergone testing with FoundationOne®. The resulting dataset is designed to provide health care providers and payers with the supporting clinical outcomes and costs evidence that inform value-based reimbursement decisions and cancer treatment.
“Eliminating inefficiencies and improving patient care requires actionable insights supported by complete, integrated data,” said Eric Schultz, CEO of COTA. “This unprecedented collaboration with Foundation Medicine incorporates the most comprehensive genomic profiling data with COTA’s unique real-world, longitudinal clinical outcomes and cost of care data to provide insights that enable both physicians and payers to move toward value-based treatment and reimbursement practices.”
Read the complete press release on Yahoo!Finance: http://yhoo.it/1x9Yj1U
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
